Ann: FDA Breakthrough Device Designation, page-58

excellent summary Sammy.
I don't think anyone doubts they will need further capital at some point in the not too distant future and this may be equity or perhaps a large JV partner (debt would probably out of the question at this point) but the potential is significant.

Todays announcement and the positive Toxicology study announcement of 23/5/19 are two significant milestones that pave the way to human trials and thereafter commercialisation (results based obviously).

The trading today overshot expectations (freefloat is only about 50% as you stated) and some are unhappy with the afternoon pullback but the way I look at it the announcement today had substance and people who were happy to hold yesterday at 2c are even more happy to hold tonight at 5.1c.

I'm happy to throw these in the bottom drawer and let the story play out but my only real concern is a takeover before the true value is realised.